Israeli Arabs are also getting in on the successes of startup nation. Doctor Amal Ayoub is the founder and CEO of Metallo-Therapy which has developed technology that better monitors malignant tumors.
Metallo-Therapy is an Israeli start-up company which is developing novel contrast agents that enable precise tumor detection and monitoring using the CT imaging tool.
MT has developed proprietary gold nanoparticles (GNP), which accumulate in malignant tumors and retain in tumors for an extended period of a few weeks. Due to their low toxicity profile and unique characteristics, in addition to their contrasting function, the GNPs can function as nano markers, supporting and enhancing multiple applications in the management of cancer patients undergoing radiotherapy.
Ayoub, a 39 year old from Nazareth, was recently profiled by both Reuters and Bloomberg. She told Reuters, “It is difficult for Arabs to be accepted at Israeli organizations. It’s difficult to be integrated into Israel’s high-tech and biotech society.”
She also explained how difficult it is for someone who never served in the IDF to make it in Israeli high tech. The army in Israel is where all of the connections are made and many of the corps people in the Israeli high tech sector served in special IDF tech units.
“I know that some Arab countries don’t like to work with Israeli companies, but I hope that might be different for a company started by an Arab woman, ” she said. “This is part of my agenda. There are not that many Arab entrepreneurs but the number has been growing rapidly missing a huge opportunity.”
Metallo-Therapy is supported by the Chief Scientist of the Israeli Ministry of Economy and by Arkin Holdings, an investment fund focused on innovative technologies in the healthcare market.